Interim Analysis Highlights Long-Term Safety of Azetukalner for Focal Epilepsy

In a further date from the ongoing open-label extension of the phase 2b X-TOLE study, results demonstrated that the majority of treatment-emergent adverse events associated with azetukalner were mild or moderate.:

Source: Neurology Read More